进一步统计，近3个月内该股累计发生5笔大宗交易，合计成交金额为1962.05万元。 欧林生物9月18日大宗交易平台出现一笔成交，成交量8.70万股，成交金额201.06万元，大宗交易成交价 为23.11元，相对今日收盘价折价15.01%。该笔交易的买方营业部为中信建投证券股份有限公司北京望 京证券营业部，卖方营业部为广发证券股份有限公司成都麓山大道证券营业部。 9月18日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 8.70 | 201.06 | 23.11 | -15.01 | 中信建投证券股份有限公 | 广发证券股份有限公司成 | | | | | | 司北京望京证券营业部 | 都麓山大道证券营业部 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，欧林生物今日收盘价为27.19元，下跌3.1 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-09-18 | 欧林生物 | 688319 | 23.11 201.06 | 8.7 | 中信建投证券股份 | 广发证券股份有限 | | | | | | | 有限公司北京望京 | 公司成都麓山大道 | | | | | | | 1 7 4 2 2 1 . 40 | ST 44 22 . 1 . 40 | 9月18日，欧林生物大宗交易成交8.7万股，成交额201.06万元，占当日总成交额的0.57%，成交价23.11元，较市场收盘价27.19元折价15.01%。 ...

Group 1 - The core viewpoint of the news is the performance and financial details of Olin Bio, which saw a stock price increase of 5.3% to 28.40 CNY per share, with a total market capitalization of 11.529 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine at 90.99% [1] - The company also generates revenue from other vaccines, including A group and C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae type b conjugate vaccine (3.99%), and others [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for the Fuyong Fund, with its Fuyong Medical Health Mixed Fund A (015655) holding 17,200 shares, representing 2.06% of the fund's net value [2] - The fund has seen a year-to-date return of 14.22% and a one-year return of 10.55%, although it has experienced a loss of 20.8% since its inception [2]

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

9月16日，在2025年半年度科创板创新药行业集体业绩说明会上，成都欧林生物科技股份有限公司(以下 简称"欧林生物")董事长、总经理樊绍文向《证券日报》记者表示："下半年，公司将继续深化相关产品 的医患教育与市场推广，巩固市场地位，同时继续深耕疫苗研发，有序推进重组金葡菌疫苗及流感疫苗 项目临床试验进展，进一步丰富产品储备。" 欧林生物副总经理、董事会秘书吴畏向《证券日报》记者表示："公司重组金葡菌疫苗拟用于预防手术 后金黄色葡萄球菌感染，属于预防用生物制品1类，目前全球范围内暂无同类产品上市。理论上，重组 金葡菌疫苗可以广泛用于医院感染相关的各个科室预防，应用前景广阔。" 与此同时，欧林生物自研的幽门螺杆菌疫苗已于2024年获得了澳大利亚的Ⅰ期临床试验许可，公司目前 正在进一步优化口服制剂，为未来国内申报临床试验奠定基础。另外，公司在研管线铜绿假单胞菌疫苗 以及鲍曼不动杆菌疫苗正在按计划推进临床前的研究工作。 此外，欧林生物不断拓宽技术平台、完善研发布局，在病毒类疫苗领域也取得了重要进展和突破。据 悉，2025年上半年，公司启动了三价及四价流感病毒裂解疫苗(MDCK细胞)Ⅰ期临床试验，并已完成受 试者入组。 ...

人民财讯9月9日电，9月8日，成都欧林生物科技股份有限公司与江苏省疾病预防控制中心在成都正式签 署战略合作框架协议。此次合作聚焦疫苗研发、疾病防控、公共卫生能力建设三大核心领域，旨在推动 科研创新、人才储备、医防融合与健康服务协同发展，重点推进创新疫苗临床研究与评价、成人接种服 务体系优化及区域传染病防控技术升级。 ...

Core Viewpoint - Oulin Biotech has shown significant stock performance with a year-to-date increase of 169.43%, despite a recent slight decline in the last five trading days [1] Group 1: Stock Performance - As of September 9, Oulin Biotech's stock price reached 28.56 CNY per share, with a market capitalization of 11.593 billion CNY [1] - The stock has experienced a 1.07% decline over the last five trading days, but a 39.32% increase over the last 20 days and a 76.62% increase over the last 60 days [1] - The company has appeared on the "龙虎榜" (top trading list) twice this year, with the latest occurrence on August 20 [1] Group 2: Financial Performance - For the first half of 2025, Oulin Biotech reported a revenue of 306 million CNY, representing a year-on-year growth of 35.17% [2] - The net profit attributable to shareholders for the same period was 13.197 million CNY, showing a substantial increase of 147.22% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 4.86% to 6,521, while the average number of circulating shares per person decreased by 4.63% to 62,169 shares [2] - The company has distributed a total of 15.434 million CNY in dividends since its A-share listing [3] - Among the top ten circulating shareholders, "兴全合润混合A" holds 15.4402 million shares, while "兴全合宜混合A" holds 8.9214 million shares, with both maintaining their holdings from the previous period [3]

Group 1 - The company, Olin Bio, announced its participation in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2]

证券代码：688319 证券简称：欧林生物 公告编号：2025-046 成都欧林生物科技股份有限公司关于参加 2025 年半 年度科创板创新药行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 09 日(星期二)至 09 月 15 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@olymvax.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 成都欧林生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度的经营成果、财务状况，公司计划于 2025 年 09 月 16 日(星期二)下午 15:00-17:00 参加 2025 年半年度科创板创新药行业集体业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 会议召开时间：2025 年 09 月 16 日(星期二)下午 15:0 ...

Summary of Key Points Core Viewpoint - The recent block trades of Olin Bio indicate a significant discount relative to the market price, suggesting potential investor interest at lower valuations [1][2]. Trading Activity - On September 5, Olin Bio recorded two block trades totaling 279,000 shares, with a transaction value of 7.0196 million yuan, at a price of 25.16 yuan per share, reflecting a 10.14% discount compared to the closing price [1]. - Over the past three months, Olin Bio has seen a total of four block trades with a cumulative transaction value of 17.6099 million yuan [2]. Market Performance - The closing price of Olin Bio on the same day was 28.00 yuan, marking a 2.38% increase, with a daily turnover rate of 2.24% and a total trading volume of 250 million yuan [2]. - The stock has experienced a decline of 5.98% over the past five days, with a net outflow of funds amounting to 31.7818 million yuan during this period [2]. Margin Trading - The latest margin financing balance for Olin Bio stands at 294 million yuan, having increased by 81.5122 million yuan, which represents a growth of 38.34% over the last five days [2].